Although Pfizer has a once-daily version of the weight-loss pill in the works, the decision still marks a blow to its ambition of entering a booming market that analysts expect to be worth $100 billion by the end of the decade.
Tag Archive for: Type 2 diabetes
The views of the five doctors, all senior physicians practicing obesity medicine at top universities and hospitals, indicate that Novo’s drug is not likely to have a significant edge based on its heart benefits, even though it will be years before Lilly produces similar cardiovascular data.
Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the product’s launch.
Following the recommendations of an independent Data Monitoring Committee, Novo Nordisk has halted a Phase III kidney outcomes study of semaglutide ahead of schedule due to strong efficacy signals.
The survey of 502 employers by Accolade, a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now.
Denmark should stop subsidizing the use of Ozempic and other so-called GLP-1 drugs for patients suffering from type 2 diabetes, and instead pay for cheaper drugs as a preferred first option, a public commission said in a recommendation issued on Tuesday.
The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim’s drugs Jardiance and Synjardy to treat type 2 diabetes in children.
Top-line results from a Phase IIa study showed that Glyscend Therapeutics’ lead candidate GLY-200 demonstrated promising safety and efficacy in patients with Type 2 diabetes, the company announced Wednesday.
The FDA has approved Lexicon Pharmaceuticals’ sotagliflozin, now to be marketed as Inpefa, as a once-daily oral medication to cut the risk of cardiovascular death and heart failure admissions and visits in adult patients with underlying heart failure, the company announced Friday.
A large trial showed that a high dose of Eli Lilly and Co.’s Mounjaro helped people with type 2 diabetes who were also obese or overweight to lose nearly 16% of their body weight, or over 34 pounds (15kg) on average, the company said on Thursday.